The mRNA Vaccine And Therapeutics Market report segments the industry into By Vaccine Type (Self-amplifying mRNA-based Vaccines, and more), By Application (Cancer, Infectious Diseases, Autoimmune Diseases, and more), By Treatment Type (Monoclonal Antibody, Gene Therapy, Cell Therapy, and more), By End User (Research Laboratories and Organizations, Hospitals and Clinics, and more), and Geography.

The mRNA vaccine and therapeutics market size is estimated to be worth USD 9 billion in 2024 and is projected to be USD 1.99 billion by 2035, representing a CAGR of -23% during the forecast period from 2024 to 2035

• The global industry was valued at US$ 19.6 Bn in 2023
• It is anticipated to advance at a CAGR of 14.6% from 2024 to 2034 and reach US$ 85.9 Bn by the end of 2034

mRNA Vaccines and Therapeutics Market Scenario

Regional Outlook

mRNA Vaccines and Therapeutics Market Snapshot

The mRNA Vaccines and Therapeutics Market estimated size and share is projected to exceed USD 253.83 billion by 2034, with a forecasted CAGR of 16.7% during the period.

mRNA Vaccines Market to grow at a significant CAGR 13.50% during 2021-2031. mRNA Vaccines Market report by BIS Research provides deep market insight, industry analysis, trends & forecast to 2031 that will help your business to grow.

The global mRNA vaccines and therapeutics market size reached USD 59.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 73.4 Billion by 2033, exhibiting a growth rate (CAGR) of 2.4% during 2025-2033. The development and acceptance of mRNA-based vaccines on a global scale, the growing need for quick and adaptable solutions for emerging and re-emerging infectious diseases, and the increasing incidence of cancer and genetic diseases are some of the major factors propelling the market.

IMARC Group provides an analysis of the key trends in each segment of the global mRNA vaccines and therapeutics market report, along with forecasts at the global, regional and country levels from 2025-2033. Our report has categorized the market based on vaccine type, treatment type, vaccine manufacturing, application, and end-user.

The value of the global mRNA combined vaccines and therapies market is forecast to reach around ** billion U.S. dollars by the end of 2030. In 2020, the market was estimated at approximately ** billion U.S. dollars. This would represent a compound annual growth rate of nearly **** percent between 2020 and 2030.More information on the global mRNA vaccines and therapies market can be found here.

mRNA Vaccines and Therapeutics Market Outlook

According to our latest research, the global mRNA vaccines and therapeutics market size reached USD 43.2 billion in 2024, reflecting the robust expansion of mRNA-based innovations across healthcare. The market is projected to grow at a CAGR of 13.4% from 2025 to 2033, resulting in a forecasted market value of USD 133.2 billion by 2033. This remarkable growth is primarily driven by the expanding adoption of mRNA technologies in infectious disease prevention, oncology, and rare genetic disorder treatments, as well as the continued investment in research and development by leading pharmaceutical and biotechnology companies.

The rapid rise in demand for mRNA vaccines and therapeutics is fundamentally fueled by the demonstrated success of mRNA platforms during the COVID-19 pandemic. The swift development, approval, and mass deployment of mRNA vaccines such as those produced by Pfizer-BioNTech and Moderna have validated the potential of this technology, not only in combating infectious diseases but also in providing a flexible and scalable platform for future pandemics. The advantages of mRNA technology—including speed of development, high efficacy, and adaptability to novel pathogens—have encouraged governments, private investors, and research institutions to accelerate funding and partnerships. This increased investment is translating into a robust pipeline of mRNA-based therapeutics targeting a wide range of diseases, further propelling market growth.

Another significant growth factor is the expanding application of mRNA therapeutics beyond infectious diseases. Pharmaceutical and biotechnology companies are leveraging the precision and versatility of mRNA technology to develop personalized cancer vaccines and treatments for genetic disorders such as cystic fibrosis and rare enzyme deficiencies. The ability of mRNA therapeutics to encode virtually any protein of interest makes them suitable for targeting previously “undruggable” diseases, opening new avenues for innovation. Clinical trial activity in oncology and rare disease segments is intensifying, with several candidates advancing to late-stage trials, which is expected to drive substantial market expansion over the next decade.

In addition, regulatory agencies are increasingly supportive of mRNA-based products, streamlining approval pathways and offering incentives for orphan drug development. The regulatory success of COVID-19 mRNA vaccines has set a precedent, leading to faster review times and greater confidence in the safety and efficacy profiles of mRNA technologies. This favorable regulatory environment, combined with growing public awareness and acceptance, is reducing barriers to market entry and accelerating the commercialization of new mRNA vaccines and therapeutics. As a result, the market is witnessing a surge in partnerships, mergers, and acquisitions aimed at consolidating expertise and expanding product portfolios.

From a regional perspective, North America continues to dominate the mRNA vaccines and therapeutics market, accounting for the largest revenue share in 2024, followed by Europe and Asia Pacific. The United States, in particular, benefits from a mature biotechnology sector, strong government support, and a well-established regulatory framework. Europe is also experiencing significant growth, driven by increased R&D investment and collaborative initiatives between academia and industry. Meanwhile, Asia Pacific is emerging as a high-growth region due to rising healthcare expenditure, expanding pharmaceutical manufacturing capabilities, and supportive government policies aimed at fostering innovation and self-reliance in vaccine and therapeutic development.

Product Type Analysis

The product type segment of the mRNA vaccines and therapeutics market is primarily divided into mRNA vaccines and mRNA therapeutics. mRNA

The global mRNA vaccines and therapeutics market was valued at USD 64.50 Billion in 2024, driven by the rising incidence of chronic diseases and increasing awareness of the widespread potential of mRNA technology across the globe. The market is expected to grow at a CAGR of 1.20% during the forecast period of 2025-2034, with the values to reach USD 72.67 Billion by 2034.

BCC Research Market Report says global market for mRNA therapeutics is expected to decline from $33 billion in 2023 to $21 billion by the end of 2028, at a CAGR of -8.6%.

The global market size of mRNA Vaccines & Therapeutics is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2024 with a CAGR of XX% from 2019 to 2024.
Global mRNA Vaccines & Therapeutics Market Report 2019 - Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global mRNA Vaccines & Therapeutics industry. The key insights of the report:
1.The report provides key statistics on the market status of the mRNA Vaccines & Therapeutics manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.
2.The report provides a basic overview of the industry including its definition, applications and manufacturing technology.
3.The report presents the company profile, product specifications, capacity, production value, and 2013-2018 market shares for key vendors.
4.The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.
5.The report estimates 2019-2024 market development trends of mRNA Vaccines & Therapeutics industry.
6.Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out
7.The report makes some important proposals for a new project of mRNA Vaccines & Therapeutics Industry before evaluating its feasibility.
There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.
For competitor segment, the report includes global key players of mRNA Vaccines & Therapeutics as well as some small players. At least 13 companies are included:
* Argos Therapeutics
* AstraZeneca
* Bayer
* BioNTech
* Boehringer Ingelheim
* CRISPR Therapeutics
For complete companies list, please ask for sample pages.
The information for each competitor includes:
* Company Profile
* Main Business Information
* SWOT Analysis
* Sales, Revenue, Price and Gross Margin
* Market Share

For product type segment, this report listed main product type of mRNA Vaccines & Therapeutics market
* Standardization Of Cancer Treatment MRNA Vaccine
* Individualized Cancer Treatment MRNA Vaccine
* Infectious Disease Treatment MRNA Vaccine
* Infection Prevention MRNA Vaccine
For end use/application segment, this report focuses on the status and outlook for key applications. End users sre also listed.
* Infectious Disease
* Cancer
* Other

For geography segment, regional supply, application-wise and type-wise demand, major players, price is presented from 2013 to 2023. This report covers following regions:
* North America
* South America
* Asia & Pacific
* Europe
* MEA (Middle East and Africa)
The key countries in each region are taken into consideration as well, such as United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.

Reasons to Purchase this Report:
* Analyzing the outlook of the market with the recent trends and SWOT analysis
* Market dynamics scenario, along with growth opportunities of the market in the years to come
* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects
* Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
* Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
* 1-year analyst support, along with the data support in excel format.
We also can offer customized report to fulfill special requirements of our clients. Regional and Countries report can be provided as well.

mRNA Vaccine and Therapeutics Market Outlook

The global mRNA Vaccine and Therapeutics market size was valued at approximately USD 46 billion in 2023 and is anticipated to reach about USD 139 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 13.2% during the forecast period. This remarkable growth can be attributed to the increasing prevalence of infectious diseases, advancements in biotechnology, and the rapid development and approval of mRNA-based COVID-19 vaccines, which have paved the way for broader applications of mRNA technology in therapeutics.

A significant driving factor for the growth of the mRNA Vaccine and Therapeutics market is the unprecedented success and efficacy of mRNA-based COVID-19 vaccines. The COVID-19 pandemic showcased the capability of mRNA technology to deliver rapid, scalable, and effective vaccine solutions. This has not only boosted public and governmental confidence in mRNA platforms but also accelerated research and investment in the field. The versatility of mRNA technology, which can be adapted swiftly for various pathogens, provides a robust foundation for the continued expansion of its applications in other infectious diseases and beyond.

Moreover, ongoing advancements in biotechnology and genetic research are propelling the development of novel mRNA therapies. The ability of mRNA technology to instruct cells to produce specific proteins opens up new avenues for treating a wide range of diseases, including cancer, cardiovascular disorders, and rare genetic conditions. Innovations in delivery mechanisms, such as lipid nanoparticles, have enhanced the stability and efficacy of mRNA therapeutics, further driving market growth. Additionally, partnerships and collaborations between pharmaceutical companies and research institutions are fostering an ecosystem conducive to rapid development and commercialization of mRNA-based products.

Another crucial growth factor is the increasing investment from both public and private sectors. Governments worldwide are recognizing the potential of mRNA technology and are funding research initiatives to explore its full capabilities. Simultaneously, venture capitalists and pharmaceutical giants are investing heavily in mRNA startups and R&D projects, aiming to capitalize on the promising future of mRNA therapeutics. These investments are not only accelerating the pace of innovation but also expanding the pipeline of mRNA-based drugs and vaccines targeting a variety of diseases.

From a regional perspective, North America holds the largest share of the mRNA Vaccine and Therapeutics market, driven by substantial R&D investments, a strong biotechnology industry, and favorable regulatory frameworks. Europe follows closely, with significant contributions from countries like Germany, the UK, and France. The Asia Pacific region is anticipated to witness the fastest growth, fueled by rising healthcare expenditure, increasing awareness about advanced therapeutics, and expanding biopharmaceutical manufacturing capabilities in countries like China and India. Latin America and the Middle East & Africa regions, while currently smaller markets, are expected to grow steadily due to improving healthcare infrastructures and increasing access to advanced medical treatments.

RNA-Based Therapeutics and Vaccines represent a transformative approach in modern medicine, offering the potential to treat a wide array of diseases beyond traditional methods. Unlike conventional vaccines and therapeutics, RNA-based solutions utilize the body's cellular machinery to produce proteins that can combat diseases directly. This innovative approach not only allows for rapid development and deployment in response to emerging health threats but also provides a platform for personalized medicine. As research and development in this field advance, the potential applications of RNA-based therapeutics and vaccines continue to expand, promising new treatments for conditions that were previously difficult to address.

Product Type Analysis

The mRNA Vaccine and Therapeutics market can be segmented by product type into mRNA Vaccines and mRNA Therapeutics. The mRNA Vaccines segment has garnered significant attention and investment, particularly due to the success of COVID-19 vaccines developed by companies such as Pfizer-BioNTech and Moderna. These vacci

mRNA Vaccines and Therapeutics Market is likely to grow at a CAGR of around 13% during the forecast period 2021-26, says MarkNtel Advisors.

As per Cognitive Market Research's latest published report, the Global mRNA vaccine market size was $1.45 Billion in 2022 and it is forecasted to reach $3.86 Billion by 2030. mRNA vaccine Industry's Compound Annual Growth Rate will be 12.8 % from 2023 to 2030. Whereas a Self-amplifying mRNA Vaccines Market Share was 61.25%, a leading type of mRNA Vaccine. What is Driving mRNA vaccine Industry Growth?

Rise in the prevalence of infectious diseases:

Recently, emerging and re-emerging infectious diseases are posing a public health threat across the globe. This era has witnessed a wave of severe infectious disease outbreaks which has had a devastating impact on lives and livelihoods around the globe. It has been studied that increasing resistances, international traveling, the risk of bio-war attacks, and infectious diseases concern the whole world.

The infectious agents not only disrupt cell growth and proliferation but also weaken the immune system which considerably decreases the body’s ability to fight cancer-causing infections. Some viruses, bacteria and parasites also cause chronic inflammation, leading to cancers.

Further, environmental changes, caused by the intensive development of industry, as a result of globalization, which in turn affects human health. It has stimulated high prevalence of infectious diseases. For instance, a high prevalence of influenza results in mild to severe illness and even death. In industrialized countries, most deaths associated with influenza occur among people aged 65 or older.

In such cases, mRNA vaccines are widely used as both RNA and delivery vehicles exhibit intrinsic immunogenicity. By triggering pattern recognition receptors within cells, synthetic RNA leads to the production of type one interferon (IFN). Thus, the rise in the prevalence of infectious diseases drives the market of mRNA vaccines market.

Mounting R&D Investment:

Health is a prime focused parameter for regulatory bodies across the world. With the increasing prevalence of communicable and non-communicable diseases, the rate of mortality has been increased dramatically. Hence the authorities are focusing on improving the healthcare system.

With the increasing healthcare requirements and associated priorities for research and development, governments and companies are investing more monetary funds into the research and development activities. For instance, the United States has invested $194.2 billion in medical and health research and development which was grew by 6.4% from 2017 to 2018.

Fuelled by the successful utilisation of the mRNA Covid-19 vaccines, RNA therapeutics is expected to make larger strides in 2023. Hence, companies are harnessing RNA research through collaborations. Researchers say this has impacted not just companies with clinical stage-products, but also individual academic labs, which will now likely result in more RNA-focused projects in the next few years.

For instance, Sanofi has launched a dedicated vaccines mRNA Center of Excellence and has invested approximately €400 million to accelerate end-to-end R&D of next-generation vaccines, fully financed through resource reallocation. Introduction of mRNA Vaccine

mRNA is a biological substance that is given in a series of shots to protect the body from developing a disease. It works by triggering the immune system to create antibodies. These antibodies then fight bacteria and viruses that cause disease. Most mRNA vaccines are multi-antigen vaccines, where mRNA has advantages over peptide-based vaccines. For more than 30 years, healthcare providers are using this technology to prevent infectious and oncological diseases. They are also studying mRNA vaccines to treat diseases like multiple sclerosis.

Moreover, mRNA vaccines are used to prevent severe illness from COVID-19 infection. Thus, 2020 was a breakout year for mRNA therapeutics with the launch and widespread use of mRNA vaccines for COVID-19.

[217+ Pages Report] The global Messenger RNA (mRNA) Vaccines & Therapeutics market size is expected to grow from USD 0.71 billion in 2021 to USD 26.35 billion by 2030, at a CAGR of 14.65% from 2022-2030

mRNA Vaccines and Therapeutics market size reached US$ 410 Million in 2024 and is expected to reach US$ 850.90 Million by 2033

In the 4th quarter of 2020, the global mRNA vaccines and therapeutics market for COVID-19 was worth some 670 million U.S. dollars. It is projected that the market will stand at about 4.9 billion dollars in Q4 2025.

According to Cognitive Market Research, the global mRNA Vaccines and Therapeutics market size will be USD 9124.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 16.20% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 3449.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 2737.35 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 2098.64 million in 2024 and will grow at a compound annual growth rate (CAGR) of 18.2% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 456.23 million in 2024 and will grow at a compound annual growth rate (CAGR) of 15.6% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 182.49 million in 2024 and will grow at a compound annual growth rate (CAGR) of 15.9% from 2024 to 2031.
The Nucleoside-modified mRNA category is the fastest growing segment of the mRNA Vaccines and Therapeutics industry

Market Dynamics of mRNA Vaccines and Therapeutics Market

Key Drivers for mRNA Vaccines and Therapeutics Market

Growing Chronic Illness Cases Fuel the Market for mRNA Vaccines and Therapeutics

The global market for mRNA vaccines and therapeutics is anticipated to rise during the forecast period due to the rising incidence of chronic diseases. For instance, the American Cancer Society's 2022 Cancer Facts & Figures estimates show that there were over 609,360 cancer-related fatalities in the US in 2022, along with an estimated 1.9 million new cancer patients. The need for creative therapeutic approaches has significantly increased with the emergence of viral and chronic diseases, including Zika, HIV, and cancer. The capacity of mRNA vaccines and therapeutics to direct the body to make its therapeutic proteins makes them special. It presents a fresh method of treating a variety of illnesses. These medicines have the potential to revolutionize healthcare delivery since they can target diseases at the molecular level. Furthermore, the NIH projects that by 2050, there will be 221.13 million Americans aged 50 and above, up 61.11% from 137.25 million in 2020—the current amount. The number of persons aged 50 and over who have at least one chronic ailment is predicted to increase by 99.5% by 2050, from 71.522 million in 2020 to 142.66 million. By 2050, there will be 14.968 million people with multimorbidity, up 91.16% from the 7.8304 million in 2020. Thus, the growing prevalence of these illnesses and the growing awareness of the potential advantages of mRNA-based therapies among patients, researchers, and healthcare professionals are driving the market for these technologies.

(Source:https://amp.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html/) (Source:https://pmc.ncbi.nlm.nih.gov/articles/PMC9881650/)

Expanding Strategic Alliances, Research and Development (R&D), and Collaborations to Drive Market Growth

The R&D, collaborations, and strategic alliances between academic institutes and key industries are accelerating the development of innovative mRNA vaccines by pooling resources, expertise, and technology to address scientific and manufacturing challenges. For instance, in January 2021, the biotechnology company Ribometrix, Inc., which develops small molecule therapeutics to treat human diseases, announced a strategic partnership with Genentech, a member of the Roche Group, to discover and develop novel RNA-targeted small molecule therapeutics to treat a range of ailments, such as cancer, neurodegenerative diseases, and infectious diseases. Likewise, in August 2024, the pharmaceutical company Eli Lilly built a 346,000-square-foot building to support RNA-based therapies. Therefore, the global market revenue for mRNA vaccines and therapies is driven by expanding strategic activities, including research and development (R&D), collaborations, and strategic alliances among research institutes and important firms.

(Source:https://ribometrix.com/news/ribometrix-announces-collaboration-with-genentech-to-discover-and-develop-rna-targeted-small-molecu...

The mRNA vaccines and therapeutics market size was over USD 9.4 billion in 2024 and is estimated to reach USD 57.5 billion by the end of 2037, expanding at a CAGR of 16.3% during the forecast timeline, i.e., 2025-2037. North America industry is predicted to account for the largest share of 57.3% by 2037, owing to the region's heightened urge for preventive therapies.

• The global industry was valued at US$ 21.7 Bn in 2023
• It is projected to grow at a CAGR of -4.3% from 2023 to 2034 and reach more than US$ 9.6 Bn by the end of 2034

Market Introduction

Regional Outlook of mRNA Vaccine Industry

Global mRNA Vaccine Market Snapshot